ECONOMIC EVALUATION OF BEVACIZUMAB VERSUS RANIBIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN CHINA

被引：0
|
作者：
Li, H. [1 ]
Li, X. [2 ]
Xie, F. [3 ]
机构：
[1] China Pharmaceut Univ, Nanjing, Jiangsu, Peoples R China
[2] Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China
[3] McMaster Univ, Hamilton, ON, Canada
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.385
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS8
引用
收藏
页码：A782 / A782
页数：1
相关论文
共 50 条
  • [21] RANIBIZUMAB AND BEVACIZUMAB FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION: A SYSTEMATIC REVIEW AND ECONOMIC EVALUATION
    Martinez Ferez, I. M.
    Flores Moreno, S.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A503 - A504
  • [22] Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration
    Gamulescu M.-A.
    Radeck V.
    Lustinger B.
    Bianca Fink B.
    Helbig H.
    [J]. International Ophthalmology, 2010, 30 (3) : 261 - 266
  • [23] Bimonthly Ranibizumab for Neovascular Age-Related Macular Degeneration
    Cohen, Salomon Yves
    Maloberti, Bertrand
    Fajnkuchen, Franck
    Nghiem-Buffet, Sylvia
    Delahaye-Mazza, Corinne
    Grenet, Typhaine
    Quentel, Gabriel
    [J]. OPHTHALMOLOGICA, 2014, 231 (02) : 80 - 85
  • [24] Ranibizumab for neovascular age-related macular degeneration - Reply
    Rosenfeld, Philip J.
    Brown, David M.
    Schneider, Susan
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (07): : 749 - 750
  • [25] COMPARISON OF INTRAVITREAL BEVACIZUMAB FOLLOWED BY RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Stepien, Kimberly E.
    Rosenfeld, Philip J.
    Puliafito, Carmen A.
    Feuer, William
    Shi, Wei
    Al-Attar, Luma
    Dubovy, Sander R.
    Murray, Timothy G.
    Davis, Janet L.
    Lee, Wen-Hsiang
    Schwartz, Stephen G.
    Smiddy, William E.
    Berrocal, Audina M.
    Flynn, Harry W., Jr.
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2009, 29 (08): : 1067 - 1073
  • [26] Treatment of neovascular age-related macular degeneration with pegaptanib and boosting with bevacizumab or ranibizumab as needed
    Farah, Samer E.
    [J]. OPHTHALMIC SURGERY LASERS & IMAGING, 2008, 39 (04) : 294 - 298
  • [27] Ocular and systemic safety of bevacizumab and ranibizumab in patients with neovascular age-related macular degeneration
    Johnson, Davin
    Sharma, Sanjay
    [J]. CURRENT OPINION IN OPHTHALMOLOGY, 2013, 24 (03) : 205 - 212
  • [28] Geographic and Demographic Variation in Use of Ranibizumab Versus Bevacizumab for Neovascular Age-related Macular Degeneration in the United States
    Gower, Emily W.
    Stein, Joshua D.
    Shekhawat, Nakul S.
    Mikkilineni, Shravani
    Blachley, Taylor S.
    Pajewski, Nicholas M.
    [J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 2017, 184 : 157 - 166
  • [29] Comparative Study of Intravitreal Bevacizumab (Avastin) versus Ranibizumab (Lucentis) in the Treatment of Neovascular Age-Related Macular Degeneration
    Landa, Gennady
    Amde, Wendewessen
    Doshi, Vatsal
    Ali, Amro
    McGevna, Laura
    Gentile, Ronald C.
    Muldoon, Thomas O.
    Walsh, Joseph B.
    Rosen, Richard B.
    [J]. OPHTHALMOLOGICA, 2009, 223 (06) : 370 - 375
  • [30] BEVACIZUMAB VERSUS RANIBIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION A Meta-analysis of Randomized Controlled Trials
    Chen, Guohai
    Li, Wensheng
    Tzekov, Radouil
    Jiang, Fangzheng
    Mao, Sihong
    Tong, Yuhua
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2015, 35 (02): : 187 - 193
12345